Mesenchymal stem cell epigenetic and immunoregulatory machinery

Mesenchymal stem cells (MSCs) are multipotent stromal cells that play a pivotal role in immune homeostasis and tissue repair through their extensive immunoregulatory pathways. These pathways are tightly controlled by epigenetic machinery, including DNA methyltransferases (DNMTs), histone deacetylases (HDACs), and histone acetyltransferases (HATs), which regulate the expression of key immunomodulatory factors such as Indoleamine 2,3-dioxygenase (IDO1) and Prostaglandin E2 (PGE2) (Galipeau & Sensébé, 2018, Nature Biomedical Engineering). The epigenetic state of MSCs determines their capacity to suppress T-cell proliferation, modulate macrophage polarization, and induce the formation of regulatory T-cells (Müller et al., 2013, Blood). In clinical settings like graft-versus-host disease (GvHD) and autoimmune disorders, the therapeutic efficacy of MSCs depends on the stability and plasticity of these epigenetic marks. Pharmacological agents such as 5-azacytidine and Vorinostat are frequently employed in research to manipulate this machinery and enhance the immunosuppressive phenotype of MSCs (Waterman et al., 2010, PLoS ONE). However, targeting these pathways presents significant challenges, including the risk of unintended gene activation and potential tumorigenicity if the epigenetic landscape is destabilized. Understanding the complex interplay between epigenetic regulation and MSC function is critical for the development of standardized and effective cell-based therapies.

Other names

MSC immunomodulatory pathwaysEpigenetic regulation of mesenchymal stem cellsMSC secretome regulationMesenchymal stromal cell signaling

Modulation of the mesenchymal stem cell (MSC) secretome and surface marker expression through the inhibition of DNA methyltransferases (DNMTs) and histone deacetylases (HDACs) to enhance or suppress immunomodulatory functions.